Teva Pharma (TEVA) Tops Q2 EPS by 3c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CRWD
5. CHKP
6. ON
7. HNGE
8. INSP
9. SPY
10. MRVL

Go back to Teva Pharma (TEVA) Tops Q2 EPS by 3c, Offers Guidance

Teva Reports Second Quarter 2023 Financial Results

August 2, 2023 7:00 AM EDT

Revenues of $3.9 billion GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56 Cash flow generated from operating activities of $324 million Free cash flow of $632 million AUSTEDO® U.S. revenues of $308 million 2023 revenues outlook revised to $15.0-$15.4 billion from $14.8-$15.4 billion; all other key components reaffirmed: Non-GAAP operating Income of $4.0 $4.4 billion Adjusted EBITDA of $4.5 - $4.9 billion Non-GAAP diluted EPS of $2.25 - $2.55 Free cash flow of $1.7 - $2.1 billion

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE... More